Latest Information Update: 04 Apr 2007
At a glance
- Originator GlaxoSmithKline
- Mechanism of Action MCHR1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Feb 2007 Discontinued - Phase-I for Obesity in United Kingdom (unspecified route)
- 22 Apr 2005 Phase-I clinical trials in Obesity in United Kingdom (unspecified route)